SPOTLIGHT: Schizophrenia drugs don't cut aggression

In a journal article sure to fuel the already-fierce debate over antipsychotic drugs, new research shows that placebo may be more effective at managing aggression in intellectually disabled patients. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.